Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: May 23, 2005
Headquarters: 8 Davis Drive, Durham, NC, United States, 27713
Founder-Led: Yes — Ben Yerxa (President and Director)
Key Metrics
Current Price
$4.65
Market Cap
$371M
Float
64.7M
Shares Outstanding
83.2M
P/E (Forward)
12.00
Price/Sales (TTM)
37.65
vs. Analyst Target
+188.4% to analyst PT
Operating Margin (TTM)
-2182.78%
Revenue (TTM)
$9.9M
Dividend Rate
None
Analyst Target Price
$13.41 (18 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
N/A
-$24.6M
-$8,000
-$17.8M
2021
$589,000
-$56.7M
$589,000
-$56.7M
2022
$39.9M
$17.9M
$39.9M
$18.2M
2023
$19.0M
-$10.0M
$19.0M
-$10.0M
2024
$11.0M
-$57.5M
$11.0M
-$57.5M
2025
$14.2M
-$49.6M
$14.2M
-$48.1M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Sep 2025
$3.1M
-$17.5M
Dec 2025
$3.9M
-$16.5M
Mar 2026
$2.2M
-$65.5M
Jun 2026
$755,000
-$8.1M
Ownership & Float
Insider Ownership
12.2%
Institutional Ownership
69.3%
Short Float
16.9%
% of All Funds Holding
1.17%
Number of Funds Holding
103
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$4.49
Near-term / short-term trend
Weekly
40-Week SMA
$4.14
Medium-term trend
Weekly
80-Week SMA
$2.78
Cyclical trend (business cycle)
Weekly
200-Week SMA
$2.66
Secular trend (multi-year)
Monthly
10-Month SMA
$4.14
Near-term monthly trend
Monthly
20-Month SMA
$2.79
Medium-term monthly trend
Monthly
40-Month SMA
$2.46
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$3.70
support
4.00x
0 months ago
$5.10
resistance
1.34x
4 months ago
$2.30
support
1.49x
7 months ago
$1.70
support
1.07x
11 months ago
Historical Earnings Reactions (70 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
-0.32%
0.00%
45.71%
19.39%
-39.60%
1 Day
-1.56%
-1.43%
28.57%
15.31%
-38.61%
1 Week
-2.29%
-1.74%
37.14%
40.21%
-37.62%
2 Weeks
-0.33%
-1.58%
40.00%
76.92%
-38.61%
1 Month
-0.71%
-3.57%
39.13%
84.62%
-48.51%
Next earnings: November 11, 2026 (31 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
11.5%
47.6%
21
Feb
9.7%
52.4%
21
Mar
1.0%
38.1%
21
Apr
-1.1%
38.1%
21
May
5.6%
52.4%
21
Jun
-3.8%
33.3%
21
Jul
-1.7%
33.3%
21
Aug
-1.0%
38.1%
21
Sep
1.9%
52.4%
21
Oct
-8.1%
30.0%
20
Nov
-6.3%
30.0%
20
Dec
-0.3%
42.9%
21
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.05%
36.9%
985
Tuesday
0.15%
37.3%
1079
Wednesday
0.10%
39.0%
1079
Thursday
0.24%
38.7%
1058
Friday
0.08%
35.2%
1054
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 69.3%
Insider Transactions — Smart Summary
Total insider ownership: 12.2%
Founder-led management: Ben Yerxa (President and Director)
12-Month Insider Activity Summary
Total Filings
19
Net Value
-$596,106.566
Net Shares Change
-6,189,726
% of Float
-9.6%
C-Suite Filings
15
Clusters Detected
3
Key Insiders
Name
Title
Net Value
Filings
Activity
Foundation Fighting Blindness Retinal Degeneration Fund
-$18.8M
3
3 sell
Gallagher Cam
+$323,693.4
1
2 buy
Gagnon Robert E.
Chief Financial Officer
-$150,154.349
2
N/A
Magrath George
Chief Executive Officer
-$27,925.668
1
N/A
YERXA BENJAMIN R
President
-$22,064.13
1
N/A
SCHACHLE JOSEPH K
Chief Operating Officer
-$13,653.36
1
N/A
Zaremba Rabourn Amy
Head of Fin. Quality Assurance
-$8,539.764
1
N/A
Transaction Clusters
Period
Filings
Insiders
Net Value
Seniority
2026-03-18 – 2026-03-18
4
4
-$180,668.024
4 C-suite
2026-04-27 – 2026-04-27
6
6
-$201,641.035
6 C-suite
2026-07-27 – 2026-07-27
4
4
-$86,585.107
4 C-suite
Significant Filings
Date
Insider
Title
Net Value
Price After
2026-10-02
Foundation Fighting Blindness Retinal Degeneration Fund
-$2.8M
Transaction at $4.96, now -6.2%
2025-12-31
Gallagher Cam
+$323,693.4
Transaction at $1.97, now +135.6%
2026-05-20
Foundation Fighting Blindness Retinal Degeneration Fund
-$7.4M
Transaction at $4.35, now +6.9%
2025-12-11
Foundation Fighting Blindness Retinal Degeneration Fund
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Opus Genetics, Inc.
(IRD) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.